Adimmune's total inventories for the quarter that ended in Dec. 2025 was NT$571 Mil. Adimmune's average total inventories from the quarter that ended in Sep. 2025 to the quarter that ended in Dec. 2025 was NT$679 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Adimmune's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was NT$-1.46.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Adimmune's Days Inventory for the
three
months ended in Dec. 2025 was 164.68.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Adimmune's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.55.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Adimmune's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.91.
Adimmune (TPE:4142) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Adimmune's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Adimmune's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Adimmune Total Inventories Related Terms
Adimmune Total Inventories Historical Data
* Premium members only.
The historical data trend for Adimmune's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Adimmune (TPE:4142) has a Total Inventories of NT$571 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Adimmune and its competitors.
Is Adimmune's Total Inventories too high?
Adimmune's current Total Inventories is NT$571 Mil. Overall, Adimmune has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adimmune's Total Inventories compare to VRTX and REGN?
Adimmune's Total Inventories of NT$571 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Adimmune and its competitors. Adimmune's current Total Inventories is NT$571 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Possible Value Trap. The stock's GF Value™ is NT$25.40, compared to a current price of NT$16.80 — trading 33.9% below its estimated fair value. The current Total Inventories is NT$571 Mil. Adimmune's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Adimmune (TPE:4142), the current Total Inventories is NT$571 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adimmune (TPE:4142) Overvalued in 2026?
Based on GuruFocus' analysis, Adimmune stock appears to be undervalued.
The current stock price of NT$16.80 is trading 33.9% below its estimated GF Value™ of NT$25.40.
GuruFocus considers Adimmune to be Possible Value Trap.
Key valuation signals for TPE:4142:
Total Inventories: NT$571 Mil
GF Value™: NT$25.40 vs. price of NT$16.80 (33.9% below fair value)
No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
55GF Score
Get the complete analysis for TPE:4142
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4142 has been successfully added to your 
